



# Corporate Overview Presentation

2024






What does **a better  
world** mean to you?

**Perhaps it's a world that's healthier.**

**Where disease is detected faster, and treatments started sooner.**

**Where the path from discovery to drug development is accelerated, so life-saving therapeutics can get to the people who need them, faster.**

**Or a world where scientific and medical research is put to work to overcome the greatest challenges of today, so we can fearlessly face the unknowns of tomorrow.**




**Welcome to **Revvity**.**

**Where "impossible" is inspiration, and "can't be done" is a call to action.**

**Every day, our 11,000+ employees worldwide collaborate to pioneer technologies, solutions, and services that help our customers redefine the health of our world.**

**Across industries, countries, and communities, our team pushes the boundaries to expand the scope of human potential.**





Who is **Revvity**?

Powering new possibilities for the future of human health

revvity


**Rev**olutionizing human health  
at an accelerated [rev] speed

Embracing impossible to  
improve lives [**vita**]

**Revvity** is a visionary partner  
in developing technologies  
and solutions across disease  
pathways to help **solve the world's  
greatest health challenges.**


We exist to expand the boundaries of  
human potential through **science.**

# Our company profile: global scale with differentiated positioning



*Expanding the  
boundaries of human  
potential through  
science*

**11,000+  
Employees Strong**



# Life Sciences at-a-glance

**~\$1.3B**

2023E Revenue

**\$20B+**

Total Addressable Market

## Pioneering innovation to propel our life sciences customers' R&D efforts


**\$0.7B**  
Reagents, Assays,  
& Services

- ✓ Reagents (antibodies, oligos) for biomarker analysis
- ✓ Flow-based assays
- ✓ Cell and gene therapy
- ✓ Single-cell applications

Select brands and products



  
Flow Cytometry

  
Oligos

Viral Vectors &  
Genetic Material

**\$0.4B**  
Instruments

- ✓ Pre-clinical imaging
- ✓ Cellular analysis
- ✓ Detection instrumentation



In Vivo  
Imaging



High-Content  
Screening



Automated  
Cell Counter

**\$0.2B**  
Software

- ✓ Robust solutions, through our Revvity Signals platform, for research and clinical informatics

revvity  
signals

 Signals  
Notebook

 Signals VitroVivo

 Signals  
Inventa

# Diagnostics at-a-glance

~\$1.4B

2023E Revenue

\$35B+

Total Addressable Market

## Leading franchises dedicated to advancing human health

**\$0.7B**  
**ImmunoDx**


- ✓ Autoimmune
- ✓ Allergy
- ✓ Infectious disease (e.g., TB)

Select brands and products

**EUROIMMUN**



Auto-immune  
Assays



Infectious  
Disease Assays

**\$0.5B**  
**Reproductive  
Health**

- ✓ Newborn screening
- ✓ Maternal and fetal health
- ✓ Cord-blood banking
- ✓ Global laboratory footprint



Newborn  
Screening  
System



Maternal &  
Fetal Health  
Assays



Prenatal  
Screening  
Platform

**\$0.2B**  
**Applied  
Genomics**

- ✓ Robust 'omics sample prep portfolio
- ✓ Liquid handling
- ✓ Nucleic acid extraction



Nucleic Acid  
Extraction




Automated  
NGS Library  
Prep



NGS  
Assays

# Bringing it all together: powering innovation from Research to Reality





How do we effectively  
serve customers from  
"Research to Reality"?

**Best-in-class quality** with  
consistency, accuracy, and  
reliability across screening  
tools and solutions



**Breadth and depth** enabling  
us to be an end-to-end, full  
spectrum provider, simplifying  
every process



**Consultative partnership** with  
a reputation for service,  
collaboration, and creating  
tailored approaches



**Diverse solutions** with the ability to scale and adjust based on a customer's unique needs, environment, and size



**Scientific expertise** and  
responsive innovation  
grounded in customer  
questions and challenges



# Making it count

- **Approximately 800 million** babies screened cumulatively for life-threatening diseases across **110 countries**
- **1,500** new Life Science antibodies, kits, and reagents introduced annually to accelerate the journey from target to cure
- **Two million scientists** across pharma, biotech, and academia supplied with Rewity's software solutions
- **550+ peer-reviewed publications** described our TB test as demonstrating excellent performance in a wide variety of settings





Sustaining our ESG  
initiatives for a  
**responsible future**

# Maintaining progress on ESG goals

## Reducing emissions

---

### Goal:

-50% reduction of Scope 1 & 2 emissions by 2033

## Waste reduction

---

### Goal:

Achieve 40% reduction in non-hazardous / non-recyclable waste going to landfills by 2027

## Employee satisfaction

---

### Goal:

Consistent employee satisfaction >75%

## Female representation

---

### Goal:

Maintain 40%+ female representation in leadership positions

Challenge limits.  
Reimagine impossible.  
Discover Revvity.

Learn more by following us on:



The background is a vibrant yellow with large, fluid, organic shapes in shades of orange and red. These shapes have a glossy, liquid-like texture with highlights and shadows. The word "revvity" is centered in a black, lowercase, sans-serif font. To the right of the text, there are several thin, black, wavy lines that resemble stylized smoke or motion lines, adding a sense of dynamism to the composition.

revvity